Welcome to our dedicated page for Athira Pharma news (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma stock.
Athira Pharma, Inc. (ATHA) is a clinical-stage biopharmaceutical company pioneering novel therapeutics targeting neurodegenerative diseases through modulation of the HGF system. This page aggregates official press releases, clinical trial updates, and strategic developments related to their pipeline of small molecule candidates.
Investors and researchers will find timely updates on regulatory milestones, partnership announcements, and scientific presentations. Key content includes progress reports on lead candidate fosgonimeton (ATH-1017) for Alzheimer's disease, updates on oral therapies ATH-1020 and ATH-1105, and analyses of biomarker-driven trial outcomes.
All materials are sourced directly from the company's investor relations communications and verified industry publications. Bookmark this page for streamlined access to Athira Pharma's latest advancements in neuroprotection research and therapeutic development.
Athira Pharma (NASDAQ: ATHA) has completed enrollment for its Phase 2 ACT-AD clinical trial, investigating ATH-1017 for mild-to-moderate Alzheimer’s disease. The trial enrolled 77 patients across the U.S. and Australia to evaluate cognitive improvements over 26 weeks. Topline results are expected in the first half of 2022. CEO Mark Litton emphasized the significance of this milestone, noting the potential for ATH-1017 to offer new treatment options. The company also plans to initiate a clinical trial for Parkinson’s disease dementia later this year.
Athira Pharma announced the appointment of Mark Litton, Ph.D., M.B.A., as the new CEO, succeeding Dr. Leen Kawas, who has resigned amid an investigation into allegations regarding her doctoral research. The special committee found that Dr. Kawas altered images in her past research, but clarified that this did not involve the company’s lead candidate, ATH-1017. This candidate is currently in late-stage development for Alzheimer’s treatment, with promising results from prior trials. The company emphasizes its commitment to integrity and scientific research.
Athira Pharma (NASDAQ: ATHA) announced updates on its ongoing Phase 2 and Phase 2/3 clinical trials for ATH-1017, a small molecule therapeutic targeting Alzheimer’s disease. The data will be presented at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) conference from Nov. 9-12, 2021. The presentation, titled "Phase 2/3 trials of ATH-1017," will be delivered by CMO Hans Moebius on Nov. 10 at 1:55 p.m. ET.
Athira Pharma, operating under the ticker ATHA, focuses on developing novel therapies to combat neurodegeneration. On August 25, 2021, Chief Medical Officer Hans Moebius will present at the Annual Biomarkers for Alzheimer’s Disease Summit, highlighting the use of Evoked-Response Potentials (ERPs), specifically ERP P300, in Alzheimer's drug development. This presentation will showcase advancements in non-invasive biomarkers utilized in Athira’s Phase 1 clinical trials.
Athira Pharma (NASDAQ: ATHA) reported significant advancements in its clinical initiatives, including the initiation of an open-label extension for the LIFT-AD and ACT-AD trials of ATH-1017. This extension allows participants to receive an additional 26 weeks of treatment, aiming to enhance understanding of long-term safety and efficacy. Financially, the company had a net loss of $14 million for Q2 2021, an increase from $2 million the previous year, with R&D expenses rising to $12 million. Cash reserves stood at $349.9 million as of June 30, 2021.
Athira Pharma, Inc. (NASDAQ: ATHA) announces the unexpected passing of Dr. Tadataka Yamada, the chair of its board of directors, effective August 5, 2021. Dr. Yamada had been with the company since June 2019 and contributed significantly to science and medicine. His background includes leadership roles in prominent healthcare organizations and awards recognizing his contributions. The company extends condolences to his family and friends. Athira Pharma focuses on developing therapies for neurodegenerative diseases, specifically advancing its lead drug candidate, ATH-1017, for Alzheimer’s and Parkinson’s dementia.
Athira Pharma (NASDAQ: ATHA) announced it will present clinical EEG data from its Phase 1 a/b trial of ATH-1017 at the Alzheimer’s Association International Conference 2021 (AAIC), taking place July 26-30, 2021. The presentation, featuring data on neurophysiological changes in Alzheimer’s patients, will be accessible on the AAIC platform and Athira's website. ATH-1017 aims to enhance the activity of Hepatocyte Growth Factor (HGF) to combat neurodegeneration, including Alzheimer's and Parkinson's dementia. The company is committed to advancing therapeutic solutions for cognitive improvement.
Athira Pharma announced the enrollment of patients in an open-label extension study for ATH-1017, a treatment for mild-to-moderate Alzheimer’s disease, following ongoing Phase 2/3 trials, LIFT-AD and ACT-AD. This extension allows for up to 26 weeks of additional therapy, generating crucial data on safety and efficacy. ATH-1017 aims to enhance cognitive function by targeting Hepatocyte Growth Factor (HGF) and its receptor, MET. Positive Phase 1a/b results showed improvement in cognitive metrics, and patent protection for ATH-1017 extends until June 2037.
A class action lawsuit has been filed against Athira Pharma (NASDAQ: ATHA) by Keller Rohrback and Longman Law, P.C. The case follows allegations of misrepresentation in Athira's IPO registration statement, particularly concerning CEO Dr. Leen Kawas. After Dr. Kawas was placed on temporary leave due to allegations of falsifying research results, Athira's stock plummeted nearly 40% from $18.24 to $11.15 per share, below the IPO price of $17.00. The lawsuit seeks remedies under the Securities Act of 1933 for affected shareholders.
Washington State University has initiated a review of potential research misconduct claims involving former student Leen Kawas, now the CEO of Athira Pharma (NASDAQ: ATHA). The Athira board has placed Kawas on temporary leave while it conducts its own investigation into her doctoral research. WSU emphasizes its commitment to high ethical standards in research and is adhering to its Executive Policy 33 for handling such allegations. Further details will be withheld until the review is concluded.
